{"id":58920,"date":"2026-03-06T13:53:05","date_gmt":"2026-03-06T05:53:05","guid":{"rendered":"https:\/\/flcube.com\/?p=58920"},"modified":"2026-03-06T13:53:06","modified_gmt":"2026-03-06T05:53:06","slug":"insilico-medicines-ai-driven-ism4808-hits-phase-i-milestone-taigen-doses-first-subject-in-ckd-anemia-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58920","title":{"rendered":"Insilico Medicine&#8217;s AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>) announced that <strong>ISM4808<\/strong>, an <strong>AI-driven PHD inhibitor<\/strong> for <strong>chronic kidney disease (CKD)-related anemia<\/strong>, has achieved its <strong>first development milestone<\/strong>. Licensee <strong>TaiGen Biotechnology<\/strong> (TaiGen*-KY, 4157) has successfully completed <strong>enrollment and dosing of the first subject<\/strong> in the <strong>Phase I clinical trial<\/strong>, triggering milestone payments under the December 2025 licensing agreement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-clinical-milestone\">Regulatory &amp; Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>ISM4808 (oral HIF-PHD inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic kidney disease (CKD)-related anemia<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>First subject enrolled and dosed in Phase I<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>TaiGen Biotechnology (TaiGen*-KY, 4157)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China (mainland China, Hong Kong, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Achievement Date<\/strong><\/td><td>March 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Phase I safety\/tolerability data readout expected H2 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>ISM4808 Profile<\/th><\/tr><\/thead><tbody><tr><td><strong>Discovery Platform<\/strong><\/td><td>Insilico Medicine&#8217;s <strong>Chemistry42<\/strong> (generative AI chemistry)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Hypoxia-inducible factor prolyl hydroxylase (HIF-PHD)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Stimulates endogenous erythropoietin (EPO) production; improves iron utilization<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Oral administration<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Best-in-class potential vs. existing IV erythropoiesis-stimulating agents (ESAs)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Clinical Advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Improved iron use efficiency vs. traditional ESAs<\/li>\n\n\n\n<li>Avoidance of intravenous injections (patient convenience)<\/li>\n\n\n\n<li>Favorable safety profile (reduced cardiovascular risk vs. ESAs)<\/li>\n\n\n\n<li>Potential to overcome hyporesponsiveness seen in current therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Structure<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>Received by Insilico (December 2025)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Development and sales-based triggers (first Phase I milestone now achieved)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on net sales<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Tens of millions of US dollars<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive development, commercialization, and sublicensing rights in Greater China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>AI Validation<\/strong><\/td><td>ISM4808 progression validates Insilico&#8217;s Chemistry42 platform for de novo drug design<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>China CKD anemia market estimated $2+ billion; oral HIF-PHD inhibitors displacing injectable ESAs<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Roxadustat (FibroGen\/AstraZeneca) first-to-market; ISM4808 targets improved safety\/efficacy profile<\/td><\/tr><tr><td><strong>Partnership Model<\/strong><\/td><td>Asset-light strategy: Insilico retains ex-China rights; TaiGen funds regional development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-platform-outlook\">Pipeline &amp; Platform Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Insilico Portfolio:<\/strong> 30+ AI-discovered programs across fibrosis, oncology, immunology; ISM4808 first CKD asset to reach clinic<\/li>\n\n\n\n<li><strong>Platform Expansion:<\/strong> Chemistry42 now deployed for multiple pharma partnerships; milestone achievement demonstrates commercial viability<\/li>\n\n\n\n<li><strong>TaiGen Strategy:<\/strong> Builds anemia franchise alongside existing portfolio; Greater China commercial infrastructure leveraged<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, milestone achievements, and commercial potential for ISM4808. Actual results may differ due to trial outcomes, regulatory requirements, and competitive dynamics in the CKD anemia market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58922,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[99,62,4514,164],"class_list":["post-58920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ai","tag-clinical-trial-approval-initiation","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine&#039;s AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia, has achieved its first development milestone. Licensee TaiGen Biotechnology (TaiGen*-KY, 4157) has successfully completed enrollment and dosing of the first subject in the Phase I clinical trial, triggering milestone payments under the December 2025 licensing agreement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58920\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine&#039;s AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia, has achieved its first development milestone. Licensee TaiGen Biotechnology (TaiGen*-KY, 4157) has successfully completed enrollment and dosing of the first subject in the Phase I clinical trial, triggering milestone payments under the December 2025 licensing agreement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58920\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-06T05:53:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-06T05:53:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine&#8217;s AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial\",\"datePublished\":\"2026-03-06T05:53:05+00:00\",\"dateModified\":\"2026-03-06T05:53:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0603.webp\",\"keywords\":[\"AI\",\"Clinical trial approval \\\/ initiation\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58920#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58920\",\"name\":\"Insilico Medicine's AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0603.webp\",\"datePublished\":\"2026-03-06T05:53:05+00:00\",\"dateModified\":\"2026-03-06T05:53:06+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia, has achieved its first development milestone. Licensee TaiGen Biotechnology (TaiGen*-KY, 4157) has successfully completed enrollment and dosing of the first subject in the Phase I clinical trial, triggering milestone payments under the December 2025 licensing agreement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58920\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine's AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58920#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine&#8217;s AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine's AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia, has achieved its first development milestone. Licensee TaiGen Biotechnology (TaiGen*-KY, 4157) has successfully completed enrollment and dosing of the first subject in the Phase I clinical trial, triggering milestone payments under the December 2025 licensing agreement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58920","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine's AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial","og_description":"Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia, has achieved its first development milestone. Licensee TaiGen Biotechnology (TaiGen*-KY, 4157) has successfully completed enrollment and dosing of the first subject in the Phase I clinical trial, triggering milestone payments under the December 2025 licensing agreement.","og_url":"https:\/\/flcube.com\/?p=58920","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-06T05:53:05+00:00","article_modified_time":"2026-03-06T05:53:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58920#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58920"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine&#8217;s AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial","datePublished":"2026-03-06T05:53:05+00:00","dateModified":"2026-03-06T05:53:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58920"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58920#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0603.webp","keywords":["AI","Clinical trial approval \/ initiation","HKG: 3696","Insilico Medicine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58920#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58920","url":"https:\/\/flcube.com\/?p=58920","name":"Insilico Medicine's AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58920#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58920#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0603.webp","datePublished":"2026-03-06T05:53:05+00:00","dateModified":"2026-03-06T05:53:06+00:00","description":"Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia, has achieved its first development milestone. Licensee TaiGen Biotechnology (TaiGen*-KY, 4157) has successfully completed enrollment and dosing of the first subject in the Phase I clinical trial, triggering milestone payments under the December 2025 licensing agreement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58920#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58920"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58920#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0603.webp","width":1080,"height":608,"caption":"Insilico Medicine's AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58920#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine&#8217;s AI-Driven ISM4808 Hits Phase I Milestone \u2013 TaiGen Doses First Subject in CKD Anemia Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58920"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58920\/revisions"}],"predecessor-version":[{"id":58923,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58920\/revisions\/58923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58922"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}